Skip to main content
. 2013 Sep 3;8(9):e74670. doi: 10.1371/journal.pone.0074670

Figure 1. Inhibition of EGFR by erlotinib downregulates PTPMeg2 leading to enhanced phosphorylation of STAT3 in head and neck cancer cells.

Figure 1

A, Tu212 and Tu686 cells were treated with erlotinib (0.1µM) for various times. Levels of various proteins (pSTAT3, PTPMeg2, pEGFR, Bcl2, Bcl-XL, etc.) were analyzed by Western blot. B, Tu212 and Tu686 cells were treated with erlotinib (0.1µM) for various times. Levels of Bcl2 or Bcl-XL mRNA were analyzed by RT-PCR.